Jean-Christophe Marine
Inventor
Stats
- 8 US patents issued
- 13 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 8 US Patents Issued
- 13 US Applications Filed
- 52 Total Citation Count
- Aug 21, 2020 Most Recent Filing
- Jul 24, 2007 Earliest Filing
Work History
Patent Owner | Applications Filed | Year |
---|---|---|
FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY | 2
1 | 2007
2013 |
ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2
2 1 | 2007
2011 2013 |
KATHOLIEKE UNIVERSITEIT LEUVEN | 2
2 2 | 2012
2014 2015 |
LEIDEN UNIVERSITY MEDICAL CENTER | 2
2 1 | 2007
2011 2013 |
UNIVERSITEIT GENT | 2
2 1 2 | 2007
2011 2013 2014 |
VIB VZW and Universiteit Gent | 1
| 2011
|
VIB VZW | 2
2 2 2 | 2011
2012 2014 2015 |
Inventor Addresses
Address | Duration |
---|---|
Brussel, BE | Sep 22, 16 - Nov 02, 17 |
Brussels, BE | Oct 10, 17 - Sep 08, 20 |
Erbisoeul, BE | Dec 03, 09 - Aug 09, 16 |
Linden, BE | Dec 17, 20 - Nov 12, 24 |
Technology Profile
Technology | Matters | |
---|---|---|
A01N: | PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF | 2 |
A61B: | DIAGNOSIS; SURGERY; IDENTIFICATION | 1 |
A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 12 |
Patents / Publication
Patents / Publication # | Year of Publication / Issued | Title | Citations |
---|---|---|---|
12139712 | 2024 | Direct and selective inhibition of MDM4 for treatment of cancer | 0 |
RE48856 | 2021 | Inhibition of NEAT1 for treatment of solid tumors | 0 |
RE48801 | 2021 | Inhibition of a lncRNA for treatment of melanoma | 0 |
2021/0008,070 | 2021 | TARGETING MINIMAL RESIDUAL DISEASE IN CANCER WITH CD36 ANTAGONISTS | 2 |
2021/0008,047 | 2021 | TARGETING MINIMAL RESIDUAL DISEASE IN CANCER WITH RXR ANTAGONISTS | 2 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.